Latest Announcements

BSE & NSE corporate filings with AI summaries

BSECompany Update▲ PositiveResults6d ago

Marksans Pharma Ltd

Press Release for Financial Results Q2FY27

Marksans Pharma Ltd reported Q2FY27 financial results, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore. H1FY27 revenue grew 32.9% to ₹1,781 crore, and PAT nearly doubled to ₹303 crore.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults6d ago

NDR Auto Components Ltd

as per attachment.

NDR Auto Components Ltd has announced its Q2 and H1FY27 financial results, showing strong growth across key financial metrics. The company's total income, EBITDA, and PAT have increased by 11.2%, 11.1%, and 7.4% respectively on a year-over-year basis. The company has also expanded its order book and capacity, and has entered into a joint venture with DYA, a leading seat supplier to Hyundai & Kia in Korea.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults6d ago

Marksans Pharma Limited

Press Release

Marksans Pharma Limited has reported its unaudited financial results for the quarter and half year ended September 30, 2026, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults6d ago

Rajshree Polypack Limited

Press Release

Rajshree Polypack Limited has announced its Q2 and H1 FY2027 financial results, with revenue from operations at ₹102.90 Crores and ₹205.81 Crores respectively, and operating EBITDA at ₹13.05 Crores and ₹27.47 Crores respectively. The company has maintained its operating margins despite a sharp rise in raw material prices and softer export demand. The results also highlight the resilience of the business, with a strong domestic revenue growth of 37.37% YoY in Q2 and a growth of 21.82% YoY in H1.

Read more →📎 1 attachment
NSEPress Release▲ PositiveJoint Venture6d ago

Ndr Auto Components Limited

Press Release

NDR Auto Components Limited has announced the formation of a joint venture with DYA Co., Ltd. to manufacture automotive seats in India for Kia India and Hyundai India. The joint venture will be incorporated in India, with NDR Auto Components holding 51% and DYA holding 49% of its share capital.

Read more →📎 1 attachment
NSEInvestor Presentation▲ Positiveinvestor_presentations6d ago

Exide Industries Limited

Investor Presentation

Exide Industries Limited has informed the Exchange about Investor Presentation, highlighting its core business, new energy business, and innovation-led capabilities. The company has a strong presence in 70+ countries, serves 120,000+ touchpoints, and has a 100% share of business on key new models with large OEMs. Exide has a diversified and resilient lead-acid business, with a portfolio spanning 2.5Ah - 20,200Ah, and a brand built over nearly 8 decades. The company has a manufacturing base with 11 plants, including 2 plants of Exide Energy Solutions Limited (EESL) and 3 lead recycling plants of Chloride Metals Limited (CML). Exide has a strong R&D centre and has initiated commercial production of lithium-ion cells, packs, and modules.

Read more →📎 1 attachment
BSECompany Update▲ PositiveJoint Venture6d ago

NDR Auto Components Ltd

as per attachment.

NDR Auto Components Ltd has announced the formation of a joint venture with Korea's DYA Co Ltd to manufacture automotive seats in India, with an investment of up to INR 62.96 crore. The joint venture will cater to Kia India and Hyundai India, and NDR Auto Components will hold 51% of the share capital.

Read more →📎 1 attachment
NSEInvestor Presentation▲ PositiveResults6d ago

Marksans Pharma Limited

Investor Presentation

Marksans Pharma Limited has informed the Exchange about Investor Presentation for Q2FY27, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults6d ago

Exide Industries Limited

Press Release

Exide Industries Limited has reported a 18.9% YoY growth in revenue and 46.7% YoY growth in PAT for H1 FY27, with a strong Q2 performance driven by healthy demand and cost optimisation initiatives.

Read more →📎 1 attachment
BSEBoard Meeting▲ PositiveResults6d ago

Dr. Lal PathLabs Ltd

Attached

Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter and half year ended September 30, 2026, along with the declaration of a 2nd interim dividend of INR 5 per equity share. The company has also appointed Ms. Vasuta Agarwal as an Additional Director and approved further investments in its subsidiary company.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults6d ago

Biocon Limited

Press Release

Biocon Limited has announced its consolidated financial results for the quarter and half-year ended September 30, 2026, with a 2% YoY increase in consolidated operating revenue to Rs 4,389 crore and a 5% YoY increase in biopharma revenue to Rs 3,583 crore.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults6d ago

Biocon Ltd

Press Release

Biocon Ltd announced its consolidated financial results for the quarter and half-year ended September 30, 2026, with a 2% YoY increase in consolidated operating revenue to Rs 4,389 crore and a 5% YoY increase in biopharma revenue to Rs 3,583 crore.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults6d ago

Keystone Realtors Limited

Press Release

Keystone Realtors Limited has announced its unaudited financial results for Q2FY27, with highest ever quarterly pre-sales of INR 14.23 billion, up 84% YoY, and highest ever quarterly PAT of INR 1.01 billion.

Read more →📎 1 attachment
← PreviousPage 92 of 926Next →